Daniel J Drucker (@DanielJDrucker) / X

Daniel J Drucker

33.1K posts

Daniel J Drucker

@DanielJDrucker

A clinician scientist at LTRI @sinaihealth studying GLP-1, diabetes, obesity and the gut endocrine system Proud 🇨🇦Not going anywhere Am 🇮🇱Chai

Toronto

Joined May 2011

Pinned
Daniel J Drucker
@DanielJDrucker
Apr 14
How do GLP-1 meds improve liver health through #weightloss independent mechanisms? Here @ChusaGzlzRellan & colleagues identify Liver Sinusoidal Endothelial Cells as direct targets of semaglutide, linking LSECs to reduction of #inflammation #Fibrosis #MASH cell.com/cell-metabolis…
13K
Daniel J Drucker
@DanielJDrucker
Jan 1, 2019
2018 accomplishments 1)Most of our knockouts had no meaningful phenotypes 2) When we increased (n) statistical significance usually disappeared 3) Many of my hypotheses flat out wrong 4)Trainees rescued me almost every time 5)Valued truth over hyperbole
Daniel J Drucker
@DanielJDrucker
Oct 3, 2025
Inflammation is a key driver of the pathophysiology of cardiometabolic disorders #obesity #T2D and new metabolic medicines based on GLP-1 action exert their magic in part by reducing inflammation. A new review from Professor Donath summarizes the field sciencedirect.com/science/articl…
32K
Daniel J Drucker
@DanielJDrucker
Nov 24, 2021
Postdoc position pls R/T-help us figure out gut hormone action-you don't have to be highly motivated, or brilliant-we aren't any of those things either. Curiosity, high ethical standards, thoughtfulness, a flair for generating reproducible (negative) results, that's how we roll
Daniel J Drucker
@DanielJDrucker
Jun 14, 2024
As GLP-1 medicines evolve to target more receptors beyond the GLP-1R, ideally exhibiting enhanced efficacy, new questions arise about long term safety. Mechanistic and outcome studies will help define the value proposition for each NCE in the clinic diabetesjournals.org/care/article/d…
103K
Daniel J Drucker
@DanielJDrucker
Jun 26, 2023
Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming
87K
Daniel J Drucker
@DanielJDrucker
Jun 4, 2021
The most effective medical therapy developed to date for #obesity the GLP-1R Agonist Semaglutide 2.4mg once weekly (Wegovy) now approved in the USA @US_FDA @novonordisk novonordisk.com/content/nncorp…
Daniel J Drucker
@DanielJDrucker
Dec 22, 2024
In 2024, it became increasingly clear that some of the clinical benefits of GLP-1 may be secondary to weight loss independent reduction of inflammation
science.org
The benefits of GLP-1 drugs beyond obesity
Glucagon-like peptide–1–based medicines have weight loss–independent actions
40K
Daniel J Drucker
@DanielJDrucker
Jan 24, 2025
As the new generation of GLP-1 medicines approaches, exciting new opportunities to assess the benefits and safety profile of new combinations diabetesjournals.org/care/article/4…
Daniel J Drucker
@DanielJDrucker
Jan 24, 2025
Subcutaneous Amycretin moves the needle with up to 22% weight loss over 36 wks in P2 #obesity @novonordisk novonordisk.com/news-and-media…
45K
Daniel J Drucker
@DanielJDrucker
Oct 4, 2024
The GLP-1 discovery and translation story-how did it happen? #diabetes #obesity #heartdisease cell.com/med/fulltext/S…
36K
Daniel J Drucker
@DanielJDrucker
Aug 30, 2020
Last week we lost a giant in the world of #diabetes, Roger Unger, a radioimmunoassay pioneer, father of modern glucagon biology, an innovator who shaped our concepts of islet biology #glucagon #T1D #T2D @hypoglycemia @JDRF @UTSWNews @theNASciences @AmDiabetesAssn
Daniel J Drucker
@DanielJDrucker
Oct 25, 2024
After a strong start, competition for @novonordisk @EliLillyandCo is coming in the #weightloss space, with widespread innovation to bring options for more people @amgen @Roche @AltimmuneInc @StructureTx @Viking_VKTX @pfizer @Boehringer economist.com/business/2024/… @TheEconomist
57K
Daniel J Drucker
@DanielJDrucker
Oct 10, 2023
Another huge win for GLP-1, semaglutide and PPL with #T2D at risk of developing #kidney disease. FLOW stopped early for efficacy @novonordisk novonordisk.com/content/nncorp…
109K
Daniel J Drucker
@DanielJDrucker
Apr 3, 2023
There are now hundreds of authoritative experts that opine daily on the risk of GLP-1 therapies, often scaring people about the risk #pancreatitis Yet after 18 years in the clinic for #T2D there is no signal for pancreatitis in RCTs or real world data thelancet.com/journals/landi…
90K